Speak directly to the analyst to clarify any post sales queries you may have.
The mRNA therapeutics market is gaining rapid traction, offering a pivotal shift in health interventions for disease prevention and treatment. Senior decision-makers across pharmaceutical and biotech sectors are increasingly evaluating mRNA technologies as essential drivers of future preventive and curative strategies in global healthcare.
Market Snapshot: mRNA Therapeutics Market Size and Growth
The mRNA therapeutics market grew from USD 41.99 billion in 2024 to USD 52.59 billion in 2025. This sector is projected to continue expanding at a CAGR of 25.41%, reaching USD 257.11 billion by 2032. Industry momentum is underpinned by accelerating innovation, supportive regulatory frameworks, and expanding clinical applications across regions.
Scope & Segmentation of the mRNA Therapeutics Market
This report delivers a comprehensive examination of the mRNA therapeutics landscape, focusing on market-defining platforms, applications, delivery innovations, and regional penetration. The analysis captures competitive positioning and strategic advances by leading companies shaping the sector's evolution.
- Technology Platform: Lipid nanoparticles, polymer-based platforms, viral vectors
- Therapeutic Application: Cardiovascular diseases, infectious disease prevention and treatment, oncology, rare genetic disorders
- Delivery Method: Intramuscular, intravenous, subcutaneous administration
- Geographic Coverage: North America (United States, Canada, Mexico), Latin America (Brazil, Argentina, Chile, Colombia, Peru), Europe (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland), Middle East (UAE, Saudi Arabia, Qatar, Turkey, Israel), Africa (South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
- Company Coverage: Moderna, Inc.; BioNTech SE; CureVac N.V.; Sanofi S.A.; Pfizer Inc.; GlaxoSmithKline plc; Arcturus Therapeutics Holdings, Inc.; Providence Therapeutics Holdings Inc.; Ethris GmbH; eTheRNA immunotherapies NV
Key Takeaways: Strategic Developments and Industry Opportunities
- mRNA therapeutics are emerging beyond infectious disease vaccines, driving clinical innovation in cardiovascular, oncology, and rare disease sectors.
- Advances in delivery systems—especially lipid nanoparticle technologies—are enhancing tissue targeting and reducing immunogenicity, broadening therapeutic reach.
- Process intensification and scale-out in GMP manufacturing are lowering barriers for new entrants, strengthening supply chain diversity and expanding capacity.
- Leading companies are consolidating their positions through proprietary technology platforms, intellectual property, and strategic partnerships focused on rapid market entry.
- Enhanced regulatory familiarity is enabling streamlined approval pathways, encouraging increased collaboration between biotech firms, pharmaceutical companies, and CDMOs.
United States Tariff Impact on Supply Chain Strategy
New tariffs introduced in 2025 are affecting cost structures and prompting value chain participants to reassess sourcing, logistics, and contractual arrangements. Larger organizations with integrated production capabilities are better positioned to offset these challenges, while smaller firms are exploring consortia, hybrid models, and strategic partnerships to sustain project milestones and cost efficiencies. Diversification of manufacturing locations and the establishment of buffer inventories are emerging as mitigation tactics, preserving agility and secure development pipelines amid evolving geopolitical pressures.
Methodology & Data Sources
Our analysis is based on a multi-source research strategy, integrating peer-reviewed literature, patent reviews, clinical trial data, and direct interviews with industry executives and scientific leaders. This approach ensures a validated, up-to-date, and actionable perspective on market trends, technological advances, and competitive dynamics.
The Importance of this mRNA Therapeutics Report
- Guides executives in identifying the highest-value opportunities and anticipating disruptive shifts across technology platforms and regions.
- Enables informed response to regulatory trends, policy shifts, and competitive moves, supporting effective long-term planning and risk mitigation.
- Empowers leaders to benchmark organizational readiness and prioritize investments—optimizing both near-term development and commercialization strategies.
Conclusion
The synthesis of market data, regulatory developments, and technology trends provides decision-makers with a comprehensive foundation to drive strategy and innovation. This report supports agile, data-driven actions, helping organizations realize the transformative potential of mRNA therapeutics in global healthcare.
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates.
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
3. Executive Summary
4. Market Overview
7. Cumulative Impact of Artificial Intelligence 2025
List of Figures
Samples
LOADING...
Companies Mentioned
The key companies profiled in this mRNA Therapeutics market report include:- Moderna, Inc.
- BioNTech SE
- CureVac N.V.
- Sanofi S.A.
- Pfizer Inc.
- GlaxoSmithKline plc
- Arcturus Therapeutics Holdings, Inc.
- Providence Therapeutics Holdings Inc.
- Ethris GmbH
- eTheRNA immunotherapies NV
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 192 |
| Published | October 2025 |
| Forecast Period | 2025 - 2032 |
| Estimated Market Value ( USD | $ 52.59 Billion |
| Forecasted Market Value ( USD | $ 257.11 Billion |
| Compound Annual Growth Rate | 25.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
